Roth Capital Fifth To Downgrade Zynerba After Trial Failure
August 08, 2017 at 15:25 PM EDT
Roth Capital analyst Michael Higgins downgraded Zynerba Pharmaceuticals to Neutral from Buy and cut his price target for the shares to $7 from $30.
